+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Myalept"

From
Myalept- Drug Insight, 2019 - Product Thumbnail Image

Myalept- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

Myalept (metreleptin) is a recombinant human leptin analog approved by the U.S. Food and Drug Administration (FDA) for the treatment of leptin deficiency and lipodystrophy in adults and children. It is used to treat endocrine and metabolic disorders, such as diabetes, obesity, and metabolic syndrome. Myalept works by increasing the body's sensitivity to leptin, a hormone that helps regulate appetite and metabolism. It is administered as a subcutaneous injection and is available in both brand-name and generic forms. Myalept is a relatively new drug in the endocrine and metabolic disorders market, but it has been gaining traction in recent years. It is used to treat a variety of conditions, including diabetes, obesity, and metabolic syndrome. It is also used to treat rare genetic disorders, such as leptin deficiency and lipodystrophy. Some companies in the Myalept market include Amgen, Takeda Pharmaceuticals, and AstraZeneca. Show Less Read more